Neuralstem in the News
Opinion: This tiny biotech company takes the real ice bucket challenge
Financial writer, Michael Brush, looks ahead of the $100 million-plus raised in the ALSA Ice Bucket Challenge to the potential of biotech treatments for ALS. Neuralstem’s recently completed NSI-566/ALS Phase II and upcoming Phase II/III trials are the focus of the opinion piece. Principal Investigator, Eva Feldman, MD, PhD, notes that she hopes “the ice bucket money goes to fast-tracking new therapies,” and Neuralstem’s President and CEO, Richard Garr, projects that, “We could be as close as two years away from commercialization.”
Research making ALS less of a mystery
CBS’s chief medical correspondent features Neuralstem NSI-566/ALS patient and trial on CBS national news story as a promising ALS treatment.
NSI-566/ALS Patient Ted Harada Interview
Paul Knoepfler, PhD, of the University of California, Davis, interviewed NSI-566/ALS Phase I patient, Ted Harada, in a two-part blog produced by the Knoepfler Lab at UC Davis School of Medicine.
UCSD Looking For Spinal Cord Injury Patients To Test Stem Cell Treatment
San Diego Public Radio & TV put out the call on behalf of the UC San Diego Health Center for spinal cord injury patients to take part in Neuralstem's FDA-approved NSI-566/cSCI Phase I trial. The injury must have occurred between one and two years ago, and be between the 7th and 12th thoracic vertebrae. UCSD's Dr. Joseph Ciacci, the study's principal investigator, is quoted and Dr. Ciacci's and Dr. Martin Marsala's research work, which "detected signs of improved motor function with minimal side effects" was cited, as were the cells' safety proven in Neuralstem's ALS trials.
Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries
Global online medical and health news service reports on UCSD researchers launching the NSI-566/cSCI clinical trial and recruiting patients. In addition to evaluating the stem cell graft's survival and the effectiveness of immunosuppression drugs to prevent rejection, the article notes that the researchers will look for therapeutic benefits such as changes in motor and sensory function, bowel and bladder function, and pain levels.
- UM researcher Eva Feldman takes on ALS, Alzheimer’s and ‘The Daily Show’
- Researchers Fret as Social Media Lift Veil on Drug Trials
- Neurogenic Drug Improves Depression in Small Trial
- ALS Breakthrough Involves Rhode Island Patient
- Neuralstem could seek partner for Phase II depression small molecule; to develop stem cell therapy solo – CEO
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.